Evommune (EVMN) Interest & Investment Income (2024 - 2026)

Evommune (EVMN) has 3 years of Interest & Investment Income data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 272.59% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.3 million, up 2.5% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.3 million, up from $1.4 million in the prior quarter.
• Over the last five years, Interest & Investment Income for EVMN reached as high as $2.3 million in Q1 2026 and fell as low as $613000.0 in Q1 2025.
• Historically, Interest & Investment Income has averaged $1.1 million across 3 years, with a median of $794500.0 in 2024.
• Across the five-year window, Interest & Investment Income soared 39.48% in 2025 and soared 272.59% in 2026, its largest moves.
• Year by year, Interest & Investment Income stood at $727000.0 in 2024, then surged by 98.49% to $1.4 million in 2025, then jumped by 58.28% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $2.3 million in Q1 2026, $1.4 million in Q4 2025, and $862000.0 in Q3 2025.